Exact Mass: 560.2417
Exact Mass Matches: 560.2417
Found 101 metabolites which its exact mass value is equals to given mass value 560.2417
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Chloramphenicol palmitate
C254 - Anti-Infective Agent > C258 - Antibiotic Same as: D01072
Isomorellic acid
Morellic acid is found in fruits. Morellic acid is from Garcinia morella (batuan Isomorellic acid is a member of pyranoxanthones. Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity[1]. Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity[1].
Sotorasib
D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors[1][2]. Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].
morellic acid
A dioxo monocarboxylic acid derived from morellin by oxidation of the aldehyde group to the corresponding carboxy group. Isolated from Garcinia morella and Garcinia hanburyi, it exhibits antineoplastic, antibacterial and anti-HIV activity. Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity[1]. Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity[1].
His Asn Gln Tyr
His Asn Tyr Gln
His Gln Asn Tyr
His Gln Tyr Asn
His Tyr Asn Gln
His Tyr Gln Asn
Met Pro Gln Trp
Met Pro Trp Gln
Met Gln Pro Trp
Met Gln Trp Pro
Met Trp Pro Gln
Met Trp Gln Pro
Asn His Gln Tyr
Asn His Tyr Gln
Asn Asn Gln Trp
Asn Asn Trp Gln
Asn Gln His Tyr
Asn Gln Asn Trp
Asn Gln Trp Asn
Asn Gln Tyr His
Asn Trp Asn Gln
Asn Trp Gln Asn
Asn Tyr His Gln
Asn Tyr Gln His
Pro Met Gln Trp
Pro Met Trp Gln
Pro Gln Met Trp
Pro Gln Trp Met
Pro Trp Met Gln
Pro Trp Gln Met
Gln His Asn Tyr
Gln His Tyr Asn
Gln Met Pro Trp
Gln Met Trp Pro
Gln Asn His Tyr
Gln Asn Asn Trp
Gln Asn Trp Asn
Gln Asn Tyr His
Gln Pro Met Trp
Gln Pro Trp Met
Gln Trp Met Pro
Gln Trp Asn Asn
Gln Trp Pro Met
Gln Tyr His Asn
Gln Tyr Asn His
Trp Met Pro Gln
Trp Met Gln Pro
Trp Asn Asn Gln
Trp Asn Gln Asn
Trp Pro Met Gln
Trp Pro Gln Met
Trp Gln Met Pro
Trp Gln Asn Asn
Trp Gln Pro Met
Tyr His Asn Gln
Tyr His Gln Asn
Tyr Asn His Gln
Tyr Asn Gln His
Tyr Gln His Asn
Tyr Gln Asn His
3,3-(3,7,12,17-Tetramethyl-8,13-divinyl-2,18-porphyrindiyl)dipro panoate
n-1,2,3,4-Tetrahydronaphth-1-yl-2-[3,5-dimethoxybenzamido]-2-deoxy-adenosine
Protoporphyrinate
D011838 - Radiation-Sensitizing Agents > D017319 - Photosensitizing Agents COVID info from COVID-19 Disease Map D003879 - Dermatologic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(2Z)-4-[(1R,3aS,5S,14aS)-8-hydroxy-3,3,11,11-tetramethyl-13-(3-methylbut-2-en-1-yl)-7,15-dioxo-5,7-dihydro-3H,11H-1,5-methanofuro[3,4-g]pyrano[3,2-b]xanthen-3a(4H)-yl]-2-methylbut-2-enoic acid
2-[(3R,6aR,8S,10aR)-1-(2-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-benzylpiperidin-1-yl)ethanone
2-[(3S,6aS,8R,10aS)-1-(2-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-[4-(phenylmethyl)-1-piperidinyl]ethanone
[(1S)-7-methoxy-9-methyl-2-(4-methylphenyl)sulfonyl-1-(3-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1R)-7-methoxy-9-methyl-2-(4-methylphenyl)sulfonyl-1-(3-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
Sotorasib
A pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations. D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors[1][2]. Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].
Protoporphyrin(2-)
The dicarboxylate anion of protoporphyrin, obtained by deprotonation of both carboxy groups.